Opko Executive Investment Will Buy 12 Months; 2008 Losses Decline

Unlike other biotechs facing a cash crunch, Opko's chief executive and biggest investor is a billionaire who has used his wealth before to keep the company afloat.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories